Introduction {#Sec1}
============

Advantages in perioperative survival have led endovascular aortic repair (EVAR) to become first-line treatment for anatomically suitable aneurysms and complicated acute type B aortic dissections \[[@CR1], [@CR2]\]. Developments in aortic stent grafts expanded the field of endovascular therapy towards thoraco-abdominal aneurysms and chronic dissections with insufficient fixation zone \[[@CR3], [@CR4]\]. In order to provide adequate graft sealing and, at the same time, preserving aortic side branch patency, the main renal arteries, celiac trunk, superior mesenteric artery and/or supra-aortic vessel are catheterized and stented via fenestrations or branches in the aortic main device. Over the last few years, fenestrated and branched EVAR procedures have increasingly been performed. Ongoing innovations in devices provide endovascular solutions for more and more challenging anatomy and pathology. The worldwide demographic shift and decreasing indications for open (surgical) aortic repair further contribute to this development. With endovascular procedure complexity, the amount of intra-arterial administered iodinated contrast media increases substantially. At the same time, new techniques like fusion image road-mapping and robotic navigation have been applied and are under further development to reduce procedural iodinated contrast volume and accelerate complex EVAR procedures \[[@CR5], [@CR6]\]. For proper risk analysis and adequate procedure management, knowledge of predictors of renal function following complex EVAR is required. Despite numerous research in the field of iodinated contrast, the effect of currently used low-osmolar intra-arterial applied iodinated contrast on short-term and long-term renal function decrease remains unclear \[[@CR7]\]. Several studies on renal outcome after endovascular aortic repair have been published, but these studies lack adjustments for contrast volume and other factors by a multivariate risk factor analysis for renal outcome \[[@CR8]--[@CR10]\].

The aim of this study was to evaluate predictors for short- and long-term renal function changes after complex fenestrated and branched endovascular aortic repair, with particular focus on risk factors for AKI and the effect of AKI on long term-renal damage.

Materials and methods {#Sec2}
=====================

This retrospective study was approved by the institutional review board; written informed consent was waived. Serum creatinine (SCr) levels and estimated glomerular filtration rate (eGFR) changes were retrospectively evaluated in 157 consecutive patients who underwent fenestrated and/or branched endovascular aortic repair for juxta-, suprarenal and thoracoabdominal aortic aneurysms between January 2006 and March 2014 at our institution. All procedures were performed under general anaesthesia. Procedural intra-arterial iodinated contrast volume (iaIC, low-osmolar, 300 mg iodine/ml) and procedure time were documented. SCr levels at baseline, during 48 h following the intervention, at discharge as well as during follow-up were retrieved from the electronic medical patient records. Corresponding eGFR levels were calculated using the Modification of Diet in Renal Disease formula \[[@CR11]\]. Patient characteristics, including age, sex, presence of diabetes and congestive heart failure, were retrieved from the medical records. Procedure-related death was recorded. Procedure-related loss of renal parenchyma was assessed by reviewing procedural angiograms together with pre- and post-procedure CT: angiographically apparent perfusion defects by intentional stent graft coverage of accessory renal arteries as well as iatrogenic renal artery injuries with occlusion of renal artery branches during the EVAR procedures were recorded. Furthermore it was assessed whether the patients received additional iodinated contrast media during computed tomography angiography (CTA) within 48 h following the EVAR procedure.

Assessment of post-EVAR acute kidney injury (AKI) {#Sec3}
-------------------------------------------------

Post-EVAR AKI was defined by comparing the individual post-EVAR SCr measurements to preoperative baseline SCr measurements. According to the definition of the Acute Kidney Injury Network criteria of AKI, patients with (1) an absolute SCr increase of at least 0.3 mg/dl and/or (2) a relative increase of at least 50 % above baseline within 48 h following the complex EVAR procedures qualified to have post-EVAR AKI \[[@CR12]\].

Decrease in eGFR during follow-up {#Sec4}
---------------------------------

The primary endpoint was decrease in eGFR at discharge. At baseline, discharge and latest moment of follow-up patients were grouped according to their eGFR into five categories: (1) eGFR \< 15 ml/min/1.73 m^2^, (2) eGFR 15--29 ml/min/1.73 m^2^, (3) eGFR 30--44 ml/min/1.73 m^2^, (4) eGFR 45--59 ml/min/1.73 m^2^ and (5) eGFR ≥ 60 ml/min/1.73 m^2^. Decrease in eGFR was defined as a transition to a category with lower eGFR when compared to baseline. Secondary endpoint was decrease in eGFR at latest moment of follow-up.

Statistical analysis {#Sec5}
--------------------

For descriptive purposes, categorical variables were presented as absolute numbers and percentages. Continuous variables were presented as a mean ± standard deviations (if normally distributed) or as a median with a range (if not normally distributed). For development of AKI, the effects of risk factors were analysed using multivariate logistic regression. For eGFR decrease at discharge of last follow-up, data were analysed with time-to-event analysis to account for differences in follow-up between patients. Multivariable Cox regression analyses were used for calculation of hazard ratios with corresponding 95 % confidence intervals. The hazard ratios represent the independent effect of predefined risk factors on the probability of an event. Observations were censored at occurrence of an event (eGFR decrease) or at the end of follow-up. Patients with transient eGFR decrease, with eGFR decrease by one category at discharge but recovery to the eGFR category at baseline, were considered as event-free at the end of follow-up. Predefined risk factors considered relevant as potential predictors were age, sex, baseline eGFR, administered contrast volume, presence or absence of AKI, additional administration of iodinated contrast within 48 h post EVAR, renal artery branch occlusion, diabetes and congestive heart failure. *P* values less than 0.05 were considered to indicate statistical significance. Analyses were performed with SPSS statistics 20.0, Chicago, Illinois.

Results {#Sec6}
=======

The study group consisted of 131 men and 26 women with a mean age of 73 ± 6 years. The distribution of baseline characteristics is presented in Table [1](#Tab1){ref-type="table"}. Median stay until discharge was 6 days (range 2--61 days, interquartile range (IQR) 3--9) and median time until last follow-up was 380 days (range 16--2762 days, IQR 117--925). One patient died perioperatively and this patient was excluded from the analysis because no data were accessible for post-EVAR renal function. Another nine patients died within 30 days (range 3--28 days) after the intervention as a result of procedure-related complications. Seven of those nine patients (78 %) developed post-EVAR AKI. Among the other 146 patients, 36 patients (24 %) developed post-EVAR AKI. In total, 43 of 156 patients (28 %) developed post-EVAR AKI. Mean procedural iaIC volume was 162 ± 77 ml (range 50--450 ml). Mean procedural iaIC volume in patients who developed post-EVAR AKI was 195 ± 88 ml (range 50--350 ml) versus 149 ± 69 ml (range 65--450 ml) in patients without post-EVAR AKI (*p* = 0.001). Mean procedure time in patients who developed post-EVAR AKI was 282 ± 138 min (range 119--603 min) versus 197 ± 89 min (range 69--395 min) in patients without post-EVAR AKI (*p* = 0.001). In 26 patients (17 %), procedure-related loss of renal parenchyma was apparent.Table 1Baseline characteristics of the entire patient population (*n* = 157) and distribution between patients with (*n* = 43) and without AKI (*n* = 113)All patientsAKINo AKIMeanStd. deviationMedian25p75pYesNoMeanStd. deviationYesMeanStd. deviationYes*P* valueAge (years)7367368777267360.801Baseline eGFR (ml/min/1.73 m^2^)6318634978641861190.263Baseline serum creatinine (μmol/l)10637978411910436110380.116Intra-arterial contrast volume (ml)1627715010020014969195880.001Procedure time (min)220110196140276282138197890.001BMI (kg/m^2^)2642624282642640.710Male gender (*n*)1312679 %86 %0.303Congestive heart failure (*n*)1514212 %9 %0.599Hypertension (*n*)827556 %51 %0.616Hyperlipidaemia (*n*)1094872 %69 %0.846Diabetes (*n*)131449 %8 %0.787CT angiography within 48 h post EVAR (*n*)5110621 %18 %0.731Accessory renal artery coverage/renal artery branch occlusion, with perfusion defect (*n*)2613131 %14 %0.02*25p* 25th percentile, *75p* 75th percentile

The results of the logistic regression analysis evaluating the independent contribution of factors for the development of post-EVAR AKI are shown in Table [2](#Tab2){ref-type="table"}. Development of AKI was significantly associated with procedure time (odds ratio (OR) per minute 1.005, 95 % CI 1.001--1.01, *p* = 0.001) and renal artery branch occlusion (OR 3.02, 95 % CI 1.12--8.16, *p* = 0.029). Although iodinated contrast volume was significantly higher in patients with AKI in the univariate analysis (Table [1](#Tab1){ref-type="table"}), iodinated contrast volume was no longer an independent risk factor for post-EVAR AKI after adjustment for other factors in the multivariate analysis.Table 2Logistic regression analysis for various risk factors for AKI within 48 h after complex EVAROdds ratio95 % CI*P* valueAge (per life-year)1.040.960--1.1270.334Sex1.3570.415--4.4320.613Diabetes1.6740.425--6.5990.426Congestive heart failure1.510.364--6.2700.571Baseline eGFR (per ml/min/1.73 m^2^)0.9930.969--1.0180.605Iodinated contrast volume (per ml)1.0030.997--1.0090.323CTA within 48 h post EVAR1.5140.532--4.3100.437Renal artery occlusion3.0211.118--8.1630.029Procedure time (min)1.0051.001--1.0100.025

Table [3](#Tab3){ref-type="table"} shows the results from the Cox proportional hazard model to assess the independent effects of predefined risk factors on probability of eGFR decrease at discharge. At discharge, the number of patients with eGFR decrease by at least one category was 37. Development of post-EVAR AKI was associated with a significantly increased risk for eGFR decrease at discharge (hazard ratio (HR) 3.47, 95 % CI 1.63--7.36; *p* = 0.001). Non-significantly but slightly increased hazard ratios were observed for accessory renal artery occlusion, iodinated contrast volume, age, male gender and patients with diabetes (*p* \> 0.05).Table 3Cox regression analysis for various risk factors for eGFR decrease by at least one category at time of hospital discharge after complex EVARHazard ratio95 % CI*P* valueAge (per life-year)1.0120.945--1.0830.74Sex1.1690.423--3.2330.763Diabetes1.9380.679--5.5290.216Congestive heart failure0.9350.265--3.3060.917Baseline eGFR (per ml/min/1.73 m^2^)0.9960.977--1.0160.722Iodinated contrast volume (per ml)1.0020.996--1.0080.58CTA within 48 h post EVAR1.2160.506--2.2190.662Renal artery occlusion1.970.866--4.4810.106Acute kidney injury3.4671.633--7.3600.001Procedure time (min)0.9970.993--1.0020.204

Table [4](#Tab4){ref-type="table"} shows the results for long-term eGFR decrease. At the moment of last follow-up, the number of patients with eGFR decrease by at least one category was 51. Patients with post-EVAR AKI had a significantly increased probability of eGFR decrease at last follow-up (HR 3.01, 95 % CI 1.56--5.80, *p* = 0.001). Procedure time, iodinated contrast volume and other patient characteristics were not significantly associated with long-term eGFR decrease.Table 4Cox regression analysis for various risk factors for eGFR decrease by at least one category at latest moment of follow-up after complex EVARHazard ratio95 % CI*P* valueAge (per life-year)1.020.964--1.0790.5Sex0.8580.393--1.8720.7Diabetes1.1130.372--3.3270.56Congestive heart failure0.4310.119--1.5620.23Baseline eGFR (per ml/min/1.73 m^2^)0.9950.978--1.0130.616Iodinated contrast volume (per ml)10.996--1.0050.868CTA within 48 h post EVAR1.1250.527--2.4020.761Renal artery occlusion1.3710.774--2.7900.384Acute kidney injury3.0131.563--5.8080.001Procedure time (min)1.0010.997--1.0040.707

Figure [1](#Fig1){ref-type="fig"} shows the distribution of eGFR categories in all patients over time. Figure [2](#Fig2){ref-type="fig"} illustrates the mean eGFR measurements over time, for subgroups with and without AKI and renal artery occlusions, respectively. Both groups start at similar baseline mean eGFR. For patients with AKI, eGFR levels decrease sharply during 48 h following complex EVAR and show substantial recovery at discharge. At the end of follow-up eGFR levels are substantially lower than at baseline for patients who developed AKI, whereas patients without AKI show only minor decrease in mean eGFR levels at the end of follow-up when compared with baseline.Fig. 1Percentage of patients per eGFR category at baseline, during 48 h following EVAR, at discharge and latest follow-up (FU)Fig. 2Mean eGFR levels with 95 % confidence interval at baseline, during 48 h post EVAR (lowest level), at hospital discharge and at latest follow-up in patients undergoing complex EVAR. Comparison of eGFR levels in patients without acute kidney injury (coded as 0; *n* = 113) and with acute kidney injury (coded as 1; *n* = 43)

Discussion {#Sec7}
==========

This study presents a retrospective evaluation of renal function changes after intra-arterial administration of high volumes of low-osmolar iodinated contrast media in a large patient population. Well-documented pre- and post-interventional renal function testing and thorough follow-up allowed us to evaluate the renal function in the postoperative period as well as beyond discharge of the patients. In multivariate regression analyses, several risk factors were evaluated regarding their association with postoperative renal function decrease. We discuss the most important findings with respect to the design of the study and current literature.

Influence of intra-arterial iodinated contrast and procedure time on short- and long-term renal function {#Sec8}
--------------------------------------------------------------------------------------------------------

For postoperative renal function decrease, which we term 'post-EVAR AKI' throughout the manuscript, we used the definition from the Acute Kidney Injury Network (AKIN) to assess post-EVAR AKI in order to provide a commonly used definition of AKI in research and clinical practice \[[@CR13]--[@CR16]\]. Another definition of contrast material-induced nephropathy (CIN) uses SCr increase of at least 0.5 mg/dl and/or at least 25 % above baseline within 72 h post intervention \[[@CR17], [@CR18]\]. When applying the CIN criteria for AKI, the patient group who developed post-EVAR AKI would have been the same in our study, excluding two patients that were not included when applying the AKIN criteria. AKIN criteria were used in our study for two main reasons: (1) we followed a recently advocated recommendation from the American College of Radiology in order to standardize the various used definitions of CIN \[[@CR19]\] and (2) post-EVAR AKI might not be due to contrast medium but might predominantly be influenced by other factors rather than low-osmolar contrast volume \[[@CR7]\]. With respect to the long-lasting discussion on the toxicity of iodinated contrast material \[[@CR7], [@CR20], [@CR21]\], we made two observations: First iodinated contrast volume was associated with a slightly increased risk for every millilitre of contrast applied; however, it was not an independent risk factor for AKI and long-term renal function decrease post EVAR in complex aneurysms. Although univariate analysis suggested a significant effect of contrast volume for the development of AKI, this effect disappeared after adjustment for procedure time. This finding corroborates the hypothesis that high contrast volume is a marker for complexity of the procedure and that patients undergoing more complex procedures have higher risk for renal function decrease. One has to be aware that in any retrospective study, observed associations are not to be confused with causative relationships. Although we found a strong association between procedure time and short-term renal function decrease, a causal relationship for procedure time itself is hereby not proven. Second, it has been questioned whether post-interventional decrease in renal function is more likely a transient subclinical \[[@CR22], [@CR23]\] or even artificial \[[@CR24], [@CR25]\] short-term phenomenon, or indeed a relevant predictor for long-term renal dysfunction. When looking at the mid- and long-term renal function measurements we made an interesting observation. While presence of AKI was a significant predictor for eGFR decrease at discharge and last follow-up, the data provide no evidence that procedure time or other factors were significantly associated with eGFR decrease beyond 48 h. Although no significant associations were found with the other risk factors, directions of the hazards ratios conform with expectations for older age, diabetes and baseline eGFR. Lack of statistical significance may be due to the limited sample size.

Accessory renal artery coverage {#Sec9}
-------------------------------

Accessory renal artery coverage and other iatrogenic renal artery side branch occlusion with consecutive visible parenchymal perfusion defect on angiogram or follow-up CTA was a significant predictor for eGFR decrease in the immediate postoperative period. Any new parenchymal perfusion defect identifiable on angiogram or CTA therefore is an indicator for short-term decrease of renal function. At discharge and latest follow-up, this risk factor was still associated with increased risk of eGFR decrease (HR = 1.970 and HR = 1.371, respectively) but this association was no longer statistically significant (*p* = 0.106 and *p* = 0.384, respectively). This finding is in line with the results from a non-randomized retrospective study, where no significant long-term renal deterioration was found in patients with accessory renal artery coverage during EVAR compared to a control group \[[@CR26]\]. In the long-term, function of the focal parenchymal mass loss seems to be maintained by the remaining renal tissue. In our study, 28 cases of accessory renal artery coverage or renal artery side branch injuries occurred, of which only two cases did not show any apparent parenchymal infarction on angiographic imaging and therefore were not included in this category. Beyond registration of infarction, no attempt was made to further quantify the diameter of the occluded renal arteries and the volume of the renal tissue defect. In accordance with a Society of Vascular Surgery consensus statement on the treatment of abdominal aortic aneurysms \[[@CR27]\], at our institution only accessory arteries smaller than or equal to 3 mm in diameter and supporting not more than one-third of the renal parenchyma are regularly overstented. This approach seems a relatively safe method at least for the long-term renal function. For larger accessory renal arteries, we cannot infer definite conclusions from our data, and any attempt to preserve their flow (e.g. with additional fenestrations) might be favourable.

In conclusion, intra-arterial iodinated contrast volume is not an independent risk factor for development of short- or long-term renal function decrease after endovascular repair of complex aortic aneurysms. Patients who develop post-EVAR AKI are at significant higher risk for long-term renal function decrease.
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